| 000 | 01190 a2200325 4500 | ||
|---|---|---|---|
| 005 | 20250511182740.0 | ||
| 264 | 0 | _c19921110 | |
| 008 | 199211s 0 0 eng d | ||
| 022 | _a0278-0232 | ||
| 024 | 7 |
_a10.1002/hon.2900100314 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMalik, I A | |
| 245 | 0 | 0 |
_aVerapamil preferentially potentiates in-vitro cytotoxicity of vincristine on malignant lymphoid cells. _h[electronic resource] |
| 260 |
_bHematological oncology _c |
||
| 300 |
_a225-31 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Resistance |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia, Lymphocytic, Chronic, B-Cell _xdrug therapy |
| 650 | 0 | 4 |
_aLeukemia-Lymphoma, Adult T-Cell _xdrug therapy |
| 650 | 0 | 4 |
_aLymphocytes _xdrug effects |
| 650 | 0 | 4 |
_aTumor Cells, Cultured _xdrug effects |
| 650 | 0 | 4 |
_aVerapamil _xpharmacology |
| 650 | 0 | 4 |
_aVincristine _xpharmacology |
| 700 | 1 | _aCostea, N V | |
| 773 | 0 |
_tHematological oncology _gvol. 10 _gno. 3-4 _gp. 225-31 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/hon.2900100314 _zAvailable from publisher's website |
| 999 |
_c1405019 _d1405019 |
||